SCHEMBL3564415

SCHEMBL3564415

COC(=O)c1ccc2ccc(NC(=O)OC(C)(C)C)cc2c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.51
KDM4E B2RXH2 2/20 0.51
PTPN11 Q06124 1/20 0.49
KAT6A Q92794 1/20 0.47
LEF1 Q9UJU2 1/20 0.46
PLAU P00749 2/20 0.45
CYP17A1 P05093 2/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA9 Q16790 1/20 0.44
NAMPT P43490 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
LCK P06239 2/20 0.43
GAA P10253 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
MAPT P10636 1/20 0.42
EPHX2 P34913 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3563135 0.96 PTPN11 (0.54) ALDH1A1KDM4EPTPN11KAT6ALEF1
SCHEMBL3567785 0.89 CYP17A1 (0.49) ALDH1A1KAT6ACYP17A1CA12CA1
SCHEMBL4315966 0.84 MEN1 (0.59) ALDH1A1KDM4EPTPN11CYP17A1NAMPT
SCHEMBL6113073 0.83 KAT6A (0.48) KDM4EKAT6APLAUCYP17A1CA12
SCHEMBL13783466 0.82 NPC1 (0.51) ALDH1A1KAT6APLAUCA12CA1
SCHEMBL15789054 0.81 RAB9A (0.61) ALDH1A1KAT6ANPC1RAB9AMEN1
SCHEMBL14037475 0.81 KAT6A (0.49) ALDH1A1KAT6ALEF1CYP17A1CA12
SCHEMBL3403454 0.81 KAT6A (0.60) ALDH1A1KDM4EKAT6ACA12CA1
SCHEMBL30216106 0.81 KAT6A (0.60) ALDH1A1KDM4EKAT6ACA12CA1
SCHEMBL1352833 0.81 MAP4K4 (0.45) LEF1CYP17A1CA12CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101044114-B Nitrobenzindoles and their use in cancer therapy AUCKLAND UNISERVICES LTD. (NZ) 2012-02-15 CN disclosed
US-7718688-B2 Nitrobenzindoles and their use in cancer therapy AUCKLAND UNISERVICES LIMITED (NZ) 2010-05-18 US disclosed
EP-1809603-A4 NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LTD (NZ) 2009-09-02 EP disclosed
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization AUCKLAND UNISERVICES LIMITED (NZ) 2008-05-22 US disclosed
CN-101044114-A Nitrobenzindoles and their use in cancer therapy AUCKLAND UNISERVICES LTD (NZ) 2007-09-26 CN disclosed
EP-1809603-A1 NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY Auckland Uniservices Limited (NZ) 2007-07-25 EP disclosed
WO-2006043839-A1 NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization HIF1AN, HYOU1, HIF1A ALDH1A1 77/4885KDM4E 856/4885PTPN11 4615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.